Cancers·Immunomodulatory triple-negative breast cancer (IM)

Countries and centresImmunomodulatory triple-negative breast cancer (IM)

Back to the Immunomodulatory triple-negative breast cancer hub →

Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.

Countries and centres

top

Every country →Coverage by country →

Cases by country

Cases by country · GLOBOCAN 2022

All countries →

No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.

Expert centres

Where the expertise is

Expert centres

3 centres in 3 countries · 0 with a trial for this cancer on record · second-opinion finder →

Choose a region from the globe in the header to mark centres near you.

3 centres


Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center Baltimore · cancer center	United States	NCI comprehensive	2,962	42,161	Multi-cancer early detection (MCED)Liquid biopsy (ctDNA)Proton therapy Proton therapy machines: cyclotrons, synchrotrons and single-room systems +2	#10
Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne Lausanne · hospital	Switzerland	none recorded	838	14,951	TIL therapy TCR-T cell therapy Immune checkpoint inhibitors Personalised neoantigen (mRNA) vaccines	-
Institut Jules Bordet Brussels · cancer center Programme: Breast International Group, Breast cancer genomics and ctDNA	Belgium	none recorded	489	8,689	Liquid biopsy (ctDNA)Monoclonal antibodies RNA sequencing & expression profiling Endocrine therapy (SERMs, AIs, SERDs)	-

These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Immunomodulatory triple-negative breast cancer but is thinly recorded here will look small.

Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.

Seeking a second opinion: ask your oncologist for a referral to a high-volume centre; most accept records and pathology by mail or telehealth. In the US, use the NCI's Find a Cancer Center tool or the nonprofit Cancer Commons, which navigates options for advanced cancers at no cost. The second-opinion finder explains how referral works in your country.

Cancers·Immunomodulatory triple-negative breast cancer (IM)

Countries and centresImmunomodulatory triple-negative breast cancer (IM)

Back to the Immunomodulatory triple-negative breast cancer hub →

Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.

Countries and centres

top

Every country →Coverage by country →

Cases by country

Cases by country · GLOBOCAN 2022

All countries →

No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.

Expert centres

Where the expertise is

Expert centres

3 centres in 3 countries · 0 with a trial for this cancer on record · second-opinion finder →

Choose a region from the globe in the header to mark centres near you.

3 centres


Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center Baltimore · cancer center	United States	NCI comprehensive	2,962	42,161	Multi-cancer early detection (MCED)Liquid biopsy (ctDNA)Proton therapy Proton therapy machines: cyclotrons, synchrotrons and single-room systems +2	#10
Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne Lausanne · hospital	Switzerland	none recorded	838	14,951	TIL therapy TCR-T cell therapy Immune checkpoint inhibitors Personalised neoantigen (mRNA) vaccines	-
Institut Jules Bordet Brussels · cancer center Programme: Breast International Group, Breast cancer genomics and ctDNA	Belgium	none recorded	489	8,689	Liquid biopsy (ctDNA)Monoclonal antibodies RNA sequencing & expression profiling Endocrine therapy (SERMs, AIs, SERDs)	-

These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Immunomodulatory triple-negative breast cancer but is thinly recorded here will look small.

Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.

Seeking a second opinion: ask your oncologist for a referral to a high-volume centre; most accept records and pathology by mail or telehealth. In the US, use the NCI's Find a Cancer Center tool or the nonprofit Cancer Commons, which navigates options for advanced cancers at no cost. The second-opinion finder explains how referral works in your country.